BACKGROUND: Previous studies have demonstrated that the adenosine monophosphate deaminase 1 (AMPD1) C34T polymorphism may be associated with survival in cardiac populations with a protective effect of the T allele. However, these studies included limited number of patients with few cardiovascular events. METHODS: We prospectively analyzed the impact of the C34T polymorphism of the AMPD1 gene in 686 unrelated white patients with stable congestive heart failure related to left ventricular systolic dysfunction. Patients underwent echocardiography, radionuclide angiography, and a cardiopulmonary exercise test. Blood samples were drawn for standard and hormonal determinations and for genetic analysis. RESULTS: There were 517 (75%) CC homozygotes, 155 (23%) CT heterozygotes, and 14 (2%) TT mutated homozygotes. We did not demonstrate any impact of this polymorphism on clinical, biologic, echocardiographic, radionuclide, and exercise parameters in the whole population and in ischemic and nonischemic subgroups of patients. During a median follow-up period of 3 years, there were 145 cardiac-related deaths and 6 urgent transplantations. There was no impact of this polymorphism on survival. CONCLUSIONS: In our population, we did not demonstrate any effect of the C34T polymorphism of the AMPD1 gene on major congestive heart failure parameters and on survival.
BACKGROUND: Previous studies have demonstrated that the adenosine monophosphate deaminase 1 (AMPD1) C34T polymorphism may be associated with survival in cardiac populations with a protective effect of the T allele. However, these studies included limited number of patients with few cardiovascular events. METHODS: We prospectively analyzed the impact of the C34T polymorphism of the AMPD1 gene in 686 unrelated white patients with stable congestive heart failure related to left ventricular systolic dysfunction. Patients underwent echocardiography, radionuclide angiography, and a cardiopulmonary exercise test. Blood samples were drawn for standard and hormonal determinations and for genetic analysis. RESULTS: There were 517 (75%) CC homozygotes, 155 (23%) CT heterozygotes, and 14 (2%) TT mutated homozygotes. We did not demonstrate any impact of this polymorphism on clinical, biologic, echocardiographic, radionuclide, and exercise parameters in the whole population and in ischemic and nonischemic subgroups of patients. During a median follow-up period of 3 years, there were 145 cardiac-related deaths and 6 urgent transplantations. There was no impact of this polymorphism on survival. CONCLUSIONS: In our population, we did not demonstrate any effect of the C34T polymorphism of the AMPD1 gene on major congestive heart failure parameters and on survival.
Authors: Arthur M Feldman; Lilin She; Dennis M McNamara; Douglas L Mann; Michael R Bristow; Alan S Maisel; Daniel R Wagner; Bert Andersson; Luigi Chiariello; Christopher S Hayward; Paul Hendry; John D Parker; Normand Racine; Craig H Selzman; Michele Senni; Janina Stepinska; Marian Zembala; Jean Rouleau; Eric J Velazquez; Kerry L Lee Journal: Cardiology Date: 2015-01-13 Impact factor: 1.869
Authors: Matthew T Wheeler; Michael Ho; Joshua W Knowles; Aleks Pavlovic; Euan A Ashley Journal: J Cardiovasc Transl Res Date: 2008-01-29 Impact factor: 4.132
Authors: Alfredo José Mansur; Rosana Seleri Fontes; Regina Airoldi Canzi; Raphael Nishimura; Airlane Pereira Alencar; Antonio Carlos Pedroso de Lima; José Eduardo Krieger; Alexandre Costa Pereira Journal: BMC Cardiovasc Disord Date: 2009-11-03 Impact factor: 2.298
Authors: Ryszard T Smolenski; Iwona Rybakowska; Jacek Turyn; Paweł Romaszko; Magdalena Zabielska; Anne Taegtmeyer; Ewa M Słomińska; Krystian K Kaletha; Paul J R Barton Journal: Cardiovasc Drugs Ther Date: 2014-04 Impact factor: 3.727